US biopharmaceutical company Privo Technologies Inc announced on Monday the launch of BeneVet Oncology, a new subsidiary aimed at improving the health and well-being of companion animals.

BeneVet is intended to leverage Privo's drug delivery technologies to address unmet medical needs in veterinary medicine. It aims to revolutionise the way diseases in pets are treated by adapting Privo's advanced platforms, originally developed for human medicine, to enhance therapeutic options for animals.

Initial research and development efforts will focus on cutaneous and subcutaneous solid tumours, targeting intratumoral therapies of solid tumours and topical treatment of shallow tumours.

BeneVet will partner with veterinarians, veterinary researchers and pet owners to ensure that its solutions are both clinically effective and practical in real-world settings. The company will also explore collaborations with animal health organisations to advance veterinary medicine through joint research initiatives.